162 related articles for article (PubMed ID: 12634724)
1. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved.
Massenkeil G; Nagy M; Lawang M; Rosen O; Genvresse I; Geserick G; Dörken B; Arnold R
Bone Marrow Transplant; 2003 Mar; 31(5):339-45. PubMed ID: 12634724
[TBL] [Abstract][Full Text] [Related]
2. [Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerism].
Beck JF; Klingebiel T; Kreyenberg H; Schaudt A; Wölle W; Niethammer D; Bader P
Klin Padiatr; 2002; 214(4):201-5. PubMed ID: 12165902
[TBL] [Abstract][Full Text] [Related]
3. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
4. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.
Huisman C; de Weger RA; de Vries L; Tilanus MG; Verdonck LF
Bone Marrow Transplant; 2007 Mar; 39(5):285-91. PubMed ID: 17262061
[TBL] [Abstract][Full Text] [Related]
7. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.
Barrios M; Jiménez-Velasco A; Román-Gómez J; Madrigal ME; Castillejo JA; Torres A; Heiniger A
Haematologica; 2003 Jul; 88(7):801-10. PubMed ID: 12857560
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R
Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682
[TBL] [Abstract][Full Text] [Related]
9. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
Koldehoff M; Steckel NK; Hlinka M; Beelen DW; Elmaagacli AH
Am J Hematol; 2006 Oct; 81(10):735-46. PubMed ID: 16838323
[TBL] [Abstract][Full Text] [Related]
11. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
[TBL] [Abstract][Full Text] [Related]
12. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity.
Massenkeil G; Roigas J; Nagy M; Wille A; Stroszczynski C; Mapara MY; Loening S; Dörken B; Arnold R
Bone Marrow Transplant; 2004 Aug; 34(4):309-16. PubMed ID: 15220955
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of chimerism in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
Furukawa T; Hashimoto S; Inano K; Yamazaki F; Takeda H; Kakihara T; Yano T; Abe T; Higuchi W; Toba K; Takahashi M; Koike T; Aizawa Y
Rinsho Ketsueki; 2001 Jun; 42(6):488-95. PubMed ID: 11505528
[TBL] [Abstract][Full Text] [Related]
14. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival.
Keil F; Prinz E; Moser K; Mannhalter C; Kalhs P; Worel N; Rabitsch W; Schulenburg A; Mitterbauer M; Greinix H
Transplantation; 2003 Jul; 76(1):230-6. PubMed ID: 12865815
[TBL] [Abstract][Full Text] [Related]
15. Establishing the method of chimerism monitoring after allogeneic stem cell transplantation using multiplex polymerase chain reaction amplification of short tandem repeat markers and Amelogenin.
Sufliarska S; Minarik G; Horakova J; Bodova I; Bojtarova E; Czako B; Mistrik M; Drgona L; Demitrovicova M; Lakota J; Krivosikova M; Kovacs L
Neoplasma; 2007; 54(5):424-30. PubMed ID: 17688372
[TBL] [Abstract][Full Text] [Related]
16. Anti-T-lymphocyte globulin based non-myeloablative stem cell transplantation followed by HLA-identical donor lymphocyte infusion for hematologic malignancies.
Mao P; Wang S; Wang H; Li Q; Xu Y; Mo W; Ying Y; Zhu Z
Chin Med J (Engl); 2003 Jan; 116(1):70-3. PubMed ID: 12667392
[TBL] [Abstract][Full Text] [Related]
17. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
Tang XW; Wu DP; Zhu ZL; Wang W; Sun AN; Qiu HY; Fu ZZ; Chang WR; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):78-81. PubMed ID: 14990044
[TBL] [Abstract][Full Text] [Related]
18. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
Bader P; Kreyenberg H; Hoelle W; Dueckers G; Handgretinger R; Lang P; Kremens B; Dilloo D; Sykora KW; Schrappe M; Niemeyer C; Von Stackelberg A; Gruhn B; Henze G; Greil J; Niethammer D; Dietz K; Beck JF; Klingebiel T
J Clin Oncol; 2004 May; 22(9):1696-705. PubMed ID: 15117992
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study.
Choi SJ; Lee KH; Lee JH; Kim S; Chung HJ; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
Bone Marrow Transplant; 2000 Aug; 26(3):327-32. PubMed ID: 10967574
[TBL] [Abstract][Full Text] [Related]
20. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
